[{"arm_notes": "", "treatment_id": null, "treatment_name": "This is a two- stage study. Stage 1: Patients will receive STC3141 60 mg/hr as an initial infusion rate which was based on phase Ia study in health volunteer and 60mg/hr is the dosage in long term infusion in phase Ia without aPTT increase; followed by a dose increase of 10 mg/hr every 6 hours until the max infusion rate is 100 mg/hr or the aPTT reaches 1.5 x ULN which ever comes first; then the infusion rate will be fixed in the rest of time. The infusion will continue at this rate for 72 hr. Stage 2: Arm 1 will receive STC3141 with the initial infusion rate decided from Stage 1 by DSMB; the dosage will be adjusted every 6 hours according to subjects\u2019 aPTT as same as stage 1. The target aPTT and Maximum dosage will be based on DSMB recommendation based on data from stage 1. The infusion last up to 120 hours; unless the patients is well enough to be discharged from ICU; or pass away or experienced intolerable adverse event etc.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1237, "treatment_name": "Stc3141", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]